Numbers of clinical trials reported that CTLA-4 mAb treatment in patients with metastatic melanoma and prostate cancer could mediate objective clinical regression and enhanced antitumor response by the improvement of effector T-cell activation of patients [38–40]. The gene discussed is CTLA4; the disease is metastatic melanoma.